Reviewing Biomerica (BMRA) & Its Competitors

Biomerica (NASDAQ: BMRA) is one of 27 publicly-traded companies in the “Diagnostic substances” industry, but how does it compare to its rivals? We will compare Biomerica to related companies based on the strength of its earnings, risk, valuation, institutional ownership, analyst recommendations, profitability and dividends.


This table compares Biomerica and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biomerica -34.95% -36.23% -23.84%
Biomerica Competitors -948.45% -42.01% -34.88%

Risk and Volatility

Biomerica has a beta of -0.9, suggesting that its stock price is 190% less volatile than the S&P 500. Comparatively, Biomerica’s rivals have a beta of 1.61, suggesting that their average stock price is 61% more volatile than the S&P 500.

Institutional & Insider Ownership

10.7% of Biomerica shares are owned by institutional investors. Comparatively, 55.5% of shares of all “Diagnostic substances” companies are owned by institutional investors. 25.7% of Biomerica shares are owned by insiders. Comparatively, 9.0% of shares of all “Diagnostic substances” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Biomerica and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Biomerica $6.69 million -$2.34 million -30.61
Biomerica Competitors $362.17 million -$16.24 million 105.71

Biomerica’s rivals have higher revenue, but lower earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and price targets for Biomerica and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomerica 0 0 2 0 3.00
Biomerica Competitors 338 863 1075 100 2.39

Biomerica presently has a consensus target price of $12.00, indicating a potential upside of 70.45%. As a group, “Diagnostic substances” companies have a potential upside of 19.43%. Given Biomerica’s stronger consensus rating and higher probable upside, research analysts clearly believe Biomerica is more favorable than its rivals.


Biomerica beats its rivals on 8 of the 13 factors compared.

Biomerica Company Profile

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily offers its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the point-of-care and in-hospital/clinical laboratories worldwide. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy, which is in clinical studies to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with's FREE daily email newsletter.